GLPwatch
Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus.
J Diabetes Investig · 2018
Last updated 2026-05-28A study of 69 obese patients with type 2 diabetes found that the drug liraglutide worked better for blood sugar control when added to insulin if patients had shorter disease duration. Those with shorter diabetes duration were 2.39 times more likely to respond well to liraglutide after stopping insulin.
AI summary of the abstract below.
| Journal | J Diabetes Investig, 2018 |
|---|---|
| Citations | 4 |
| Relative citation ratio | 0.12 |
| NIH percentile | 8 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes |
Abstract
Comment on the article of Usui et al. Retrospective cohort study of obese patients with type 2 diabetes mellitus (n = 69) demonstrates that the glucose-lowering effect of liraglutide as add on therapy to insulin relies on the remaining beta-cell function in type 2 diabetes. Shorter disease duration implies a more favourable prognosis for response on instantaneous substitution of insulin with liraglutide (HR 2.39 (95% CI: 1.20-4.76).
Verbatim abstract via PubMed 29974671 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.